The latest price of a box of Dasatinib tablets

Dasatinib (Dasatinib) is a highly effective second-generation BCR-ABL tyrosine kinase inhibitor, which is widely used in the treatment of malignant hematological tumors such as chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (Ph+ ALL). This drug blocks the proliferation and survival of cancer cells by inhibiting the activity of abnormal signaling pathways. It is currently one of the important choices for the treatment of patients with drug resistance or intolerance to imatinib in the world. The emergence of dasatinib has brought longer survival and better quality of life to many patients with refractory leukemia, so it is clinically regarded as an important milestone drug in the field of targeted therapy.

Currently, dasatinib has been approved for marketing by the State Food and Drug Administration in mainland China under the trade name Sprycel (Sprycel). The drug has been included in the Category B item of the medical insurance catalog, and the reimbursement scope is mainly limited to CML or Ph+ ALL patients who meet the diagnosis and treatment standards. Its common packaging specifications are 50mg×60 tablets and 20mg×60 tablets. The market price of each box is about 10,000 yuan. After medical insurance reimbursement, the patient’s out-of-pocket payment is significantly reduced, allowing more patients to take long-term medication for maintenance treatment. Compared with domestic ones, the pricing of original drugs in overseas markets is more expensive, usually exceeding US$10,000 per box.

However, as the patent protection period gradually expires, many countries and regions have launched generic drugs of dasatinib. Its pharmaceutical ingredients are the same as the original drug and the efficacy is equivalent, but the price is more accessible. Pharmaceutical companies in countries such as India and Bangladesh produce and export high-quality generic versions of dasatinib. The selling price of these drugs in the international market is usually only a few hundred to thousands of yuan. The specific price will be affected by factors such as exchange rates, production costs, and local policies.

In short, whether it is an original drug or a generic drug, dasatinib belongs to the category of prescription drugs and must be used under the guidance of an experienced hematologist or oncologist.

Reference materials:https://go.drugbank.com/drugs/DB01254